Douglas Dodson, DO
Neuromusculoskeletal Medicine, Sports Medicine · Alamogordo, NMNPI 1861464844
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $25,528 of the $25,879 with a category attached, or 98.6%. Kyocera Medical Technologies, Inc. accounts for 65.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $8,725 and has fallen 50.5% since, to $4,317 in 2023.
Across 24 payments — averaging $1078.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyocera Medical Technologies, Inc.$17K
- Renovis Surgical Technologies, Inc.$9K
- Abbott$289
- Johnson & Johnson$25
- Zimmer Biomet$24
- Orthofix Medical, Inc.$13
Across 31 payments — averaging $402.96 each. An ownership or investment interest held by the physician or an immediate family member.
- Midwest Surgical Alliance, LLC$8K
- Central California Surgical Distributors, LLC$2K
- Sequoia Surgical Distributors, LLC$2K
- Renovis Surgical Technologies, Inc.$0
- North Idaho Surgical Cooperative, LLC$0
- Senate Surgical Distribution, LLC$0
What the payments were for
- Royalty or licence$25,52899%
- Food & beverage$3511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyocera Medical Technologies, Inc. | 4 | $16,829 |
| Renovis Surgical Technologies, Inc. | 1 | $8,699 |
| Abbott | 14 | $289 |
| Johnson & Johnson | 1 | $25 |
| Zimmer Biomet | 1 | $24 |
| Orthofix Medical, Inc. | 3 | $13 |
How this compares
Too few neuromusculoskeletal medicine, sports medicine providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 68 | $1,002 |
| Methylprednisolone | 101 | $875 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 94 | $824 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 66 | $519 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 34 | $285 |
| Warfarin Sodium | 41 | $162 |
| Tramadol Hcl | 36 | $137 |
| Meloxicam | 24 | $69 |
Paid to pharmacies, not to this prescriber.
Other neuromusculoskeletal medicine, sports medicine in Alamogordo
- Eric FreehAlamogordo$807
- Paul LeskoAlbuquerque$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.